US Pharm. 2010;35(11):84. 

Two generic pharmaceutical makers, Sandoz and Teva, have announced the launches of pramipexole dihydrochloride tablets, a generic equivalent of Mirapex (Boehringer Ingelheim). The drug is indicated to treat the signs and symptoms of idiopathic Parkinson's disease, which affects approximately 500,000 people in the United States, with about 50,000 new cases reported annually. Sandoz is marketing pramipexole dihydrochloride tablets in 0.125-mg, 0.25-mg, 0.5-mg, 0.75-mg, 1-mg, and 1.5-mg strengths. Teva is marketing pramipexole dihydrochloride tablets in 0.75-mg strength.